Viewing nowCombinationRodistal Tablet 40/5 mg (Telmisartan, Amlodipine Besylate)
Telmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Medica Korea Co., Ltd.

MFDS item code 201901005 · Approved 2019.02.19 · Insurance code 646004630
Treatment of essential hypertension not controlled by monotherapy
This medication is recommended for patients with essential hypertension whose blood pressure is not adequately controlled with either amlodipine or telmisartan alone. It aids in dilating blood vessels to reduce blood pressure and is effective in reducing the cardiovascular risks associated with hypertension. It plays a crucial role in the prevention of complications by managing essential hypertension reliably. Thus, it is used by individuals who require proper blood pressure control.
The recommended dose of this drug is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, a direct switch to this drug may be considered. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this drug 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. Patients taking telmisartan and amlodipine concomitantly may switch to this drug (a fixed-dose combination with the same amount of each active ingredient) for convenience (limited to this drug 40/5 milligrams). ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine dosage is recommended for elderly patients, but caution should be exercised when increasing the dose. (See section ‘3. Patients requiring caution in administration’.) In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually.
Pediatric patients aged 18 years or younger: The safety and efficacy of this drug have not been established; therefore, its use is not recommended.
This medication can cause serious side effects to the fetus or newborn, especially during the second and third trimesters of pregnancy; therefore, it should not be taken by pregnant women or women who may become pregnant. It should not be administered to patients with an allergy to this medication or similar drugs, nursing mothers, patients with obstructive biliary disease, severe liver impairment, or specific heart-related diseases. Particular care should be taken when using this medication in patients with primary aldosteronism, certain heart valve diseases, liver impairment, gastrointestinal diseases, renal vascular diseases, renal failure, and elderly individuals. Common side effects include dizziness and peripheral edema, and rarely, serious side effects like fainting or cardiac issues may occur. During pregnancy, use of this medication poses risks such as decreased renal function in the fetus, delayed skull formation, and renal failure in the newborn; therefore, use should be discontinued immediately upon confirmation of pregnancy, and consultation with a physician is necessary. As this medication lowers blood pressure, patients with hypotension or dehydration should manage their condition prior to taking it and should take it under a physician's guidance. There is a risk of elevated potassium levels, so patients at risk for hyperkalemia should have regular blood tests and careful monitoring. Patients with impaired kidney function should monitor their renal functionality regularly while taking this medication, and its safety in kidney transplant recipients has not been established. One of the components of this medication may increase the risk of angina or myocardial infarction in some heart disease patients, so caution is advised when taken by patients with heart diseases. This medication may cause drowsiness or dizziness; therefore, caution should be exercised when driving or operating heavy machinery while on this medication. Interactions may occur with other antihypertensives or specific medications, so inform the physician or pharmacist of any other medications being taken. Pregnant or nursing women should not take this medication, and consultation with a healthcare provider is necessary if there are plans for pregnancy or if pregnancy occurs. The safety and efficacy in pediatric patients have not been sufficiently established; therefore, it is advised that individuals under 18 years of age do not use this medication. Elderly patients may react more sensitively to this medication; therefore, dosages should be adjusted and managed carefully. In cases of overdose, the risk of severe hypotension and cardiac function decline exists; immediate medical attention is required.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that does not allow light to enter. To maintain the medication's efficacy, it is best stored at a temperature between 1 to 30 degrees Celsius.
A white and light gray, double convex, oval-shaped tablet.
For domestic use - 30 tablets/PTP [30 tablets (10 tablets/Alu-Alu X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.